Maridebart Cafraglutide for diabetes mellitus, type 2

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 23 May 2025: Trial registered, NCT06987695
  2. 13 Jun 2025: Trial started, NCT06987695
  3. 6 Jul 2026: Trial registered, NCT07684144
  4. 29 Jul 2026: Trial started, NCT07684144

The trials

NCT06987695: Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease

State
Under way
Phase
Phase 3
People
279 taking part
Started
13 Jun 2025
Primary completion
27 Apr 2027
Arms
Maridebart Cafraglutide High Dose, Maridebart Cafraglutide Medium Dose, Maridebart Cafraglutide Low Dose
Results
None posted
  1. 23 May 2025: Trial registered
  2. 13 Jun 2025: Trial started

NCT07684144: Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

State
Under way
Phase
Phase 3
People
950 planned
Started
29 Jul 2026
Primary completion
26 Dec 2027
Arms
Maridebart Cafraglutide Low Dose Q4W, Maridebart Cafraglutide Medium Dose Q4W, Maridebart Cafraglutide Medium dose Q8W, Maridebart Cafraglutide High Dose Q4W, Maridebart Cafraglutide High Dose Q8W, Maridebart Cafraglutide High Dose Q4W (Received Placebo in the Parent Trial), Maridebart Cafraglutide Low Dose Q4W(Received Very Low Dose Maridebart Cafraglutide in Parent Trial)
Results
None posted
  1. 6 Jul 2026: Trial registered
  2. 29 Jul 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.